C. difficile

Pfizer fails phase 3 C. diff vaccine test but still spies possible path forward
Fierce Biotech
Tue, 03/1/22 - 10:37 am
Pfizer
clinical trials
vaccines
C. difficile
Vedanta brings home a win for lead microbiome program, passing a PhII test and clinching BARDA investment
Endpoints
Tue, 10/5/21 - 10:54 am
Vedanta Biosciences
microbiome
clinical trials
C. difficile
BARDA
CRISPR Technology Edges Closer to Commercial Use
BioSpace
Thu, 10/1/20 - 11:13 pm
CRISPR
C. difficile
PureTech’s Vedanta Biosciences gets federal funding for C. Diff. microbiome therapy
Pharmaforum
Wed, 09/30/20 - 11:03 pm
Vedanta Biosciences
microbiome
C. difficile
BARDA
Battered and bruised Seres Therapeutics see shares skyrocket on phase 3 win
Fierce Biotech
Tue, 08/11/20 - 11:35 am
Seres Therapeutics
SER-109
C. difficile
microbiome
In big year for microbiome drugs, a small biotech sets the bar
BioPharma Dive
Fri, 06/19/20 - 11:22 am
biotech
microbiome
Finch Therapeutics
C. difficile
Ferring’s gut microbiome drug clears phase 3 trial in C. diff
Pharmaforum
Thu, 05/7/20 - 10:41 am
Ferring Pharmaceuticals
clinical trials
microbiome
C. difficile
RBX2660
FDA Approves Merck's Dificid for Infections in Children
Motley Fool
Mon, 01/27/20 - 10:52 pm
FDA
Merck
Dificid
pediatric
C. difficile
MGB tops up cash pool to wrap up antibiotic phase 2a
Fierce Biotech
Fri, 08/30/19 - 10:29 am
MGB Biopharma
antibiotics
MGB-BP-3
C. difficile
clinical trials
Microbiome company Finch raises $53M ahead of anti-infective readout
BioCentury
Fri, 08/23/19 - 09:51 am
microbiome
Finch Therapeutics
C. difficile
Microbiome-Focused Seres Therapeutics Inc. Announces Proposed Common Stock Offering
CP Wire
Thu, 06/13/19 - 09:56 am
Seres Therapeutics
C. difficile
ulcerative colitis
Microbiome-Focused Seres Therapeutics Inc. Announces Proposed Common Stock Offering
Thu, 06/13/19 - 09:54 am
Seres Therapeutics
C. difficile
ulcerative colitis
Investigational Live Microbial Drug Granted Breakthrough Therapy Designation for Recurrent C. Difficile
CP Wire
Fri, 02/8/19 - 09:42 am
Finch Therapeutics
CP101
C. difficile
microbiome
Investigational Live Microbial Drug Granted Breakthrough Therapy Designation for Recurrent C. Difficile
Fri, 02/8/19 - 09:37 am
Finch Therapeutics
CP101
C. difficile
microbiome
Rebiotix to Report on Development of its Microbiome Health Index
CP Wire
Mon, 10/22/18 - 10:07 am
Rebiotix
C. difficile
Rebiotix to Report on Development of its Microbiome Health Index
Mon, 10/22/18 - 09:31 am
Rebiotix
C. difficile
Rebiotix to Present Data From First-In-Class Microbiota Restoration Therapy at IDWeek 2018
CP Wire
Tue, 10/2/18 - 09:54 am
Rebiotix
RBX2660
C. difficile
microbiome
Rebiotix to Present Data From First-In-Class Microbiota Restoration Therapy at IDWeek 2018
Mon, 10/1/18 - 11:29 pm
Rebiotix
RBX2660
C. difficile
microbiome
Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile in Ph II Trial
CP Wire
Fri, 08/3/18 - 11:04 am
Summit Therapeutics
C. difficile
microbiome ridinilazole
J&J dumps a failed PhIII antibiotic program picked up in Actelion buyout
Endpoints
Tue, 04/17/18 - 11:08 am
JNJ
Actelion
antibiotics
C. difficile
cadazolid

Pages